A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Completed · Phase 3 · NCT03141177
Conditions: Renal Cell Carcinoma
At a glance
- Research payments reported, 2025
- $7,820
- U.S. investigators named
- 3
- Sites paid
- 2
- Planned or actual enrollment
- 701
About the trial
- Sponsor
- Bristol-Myers Squibb (with Exelixis, Ono Pharmaceutical Co., Ltd.)
- Tested
- Nivolumab (biological), Cabozantinib (drug), Sunitinib (drug), Ipilimumab (biological)
- Dates
- Started 2017-07-23; completion 2026-04-01
- Results posted
- Yes
The purpose of this study is to determine whether Nivolumab Combined with Cabozantinib is safe and effective compared to Sunitinib in previously untreated advanced or metastatic renal cell carcinoma
From ClinicalTrials.gov, last updated 2026-08-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $7,820 in research payments for this study in 2025 (5 payments).
Products named: Opdivo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Michael W. Meshad, MD Medical Oncology · Mobile, AL
- Charles L. Cowey, M.D. Medical Oncology · Dallas, TX
- Jeffrey T. Yorio, MD Hematology & Oncology · Austin, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Texas Onco Southwest Fort Worth $6,885
- Southern Cancer Center $935
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.